{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-067810","form_type":"8-K","ticker":"FRMM","cik":"0001690080","company_name":"FORUM MARKETS Inc","filed_at":"2023-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.868116+00:00","generated_at":"2026-06-11T09:28:53.271901+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"180 Life Sciences closes $3M public offering of 4.6M shares and warrants at $0.65","bullets":["Offering of 4,615,385 shares (or equivalents) and warrants to purchase 4,615,385 shares at $0.65 per unit.","Gross proceeds ~$3M; net proceeds ~$2.6M after placement agent fees and expenses.","Proceeds to fund R&D and marketing authorization application for Dupuytren's Contracture in UK and possibly US.","Existing warrants for 4,448,713 shares amended: exercise price reduced from prior level to $0.83.","Placement agent A.G.P./Alliance Global Partners; 90-day lock-up for directors and officers."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-067810","json":"https://secwatch.observer/filing/0001213900-23-067810.json","markdown":"https://secwatch.observer/filing/0001213900-23-067810.md","text":"https://secwatch.observer/filing/0001213900-23-067810.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690080/000121390023067810/0001213900-23-067810-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690080/000121390023067810/ea183547-8k_180life.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T09:28:53.271901+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"240f1c7061dc77ce70d0f8db2b1ca68e61da87ea","claim":"FORUM MARKETS Inc entered into Placement Agency Agreement with A.G.P./Alliance Global Partners (effective 2023-08-09).","evidence_excerpt":"On August 9, 2023, the Company also entered into a placement agency agreement (the “ Placement Agency Agreement ”) with A.G.P./Alliance Global Partners (the “ Placement Agent ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690080/000121390023067810/0001213900-23-067810-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"A.G.P./Alliance Global Partners"},{"label":"Effective","value":"2023-08-09"}],"fact_type":"material_agreement"},{"claim_id":"8144c25dd55ac7dbae9711fb1184c1f6c702baeb","claim":"FORUM MARKETS Inc amended Warrant Amendment Agreement with the Institutional Investor (effective 2023-08-09).","evidence_excerpt":"In connection with the Offering, the Company entered into a warrant amendment agreement (the “ Warrant Amendment Agreement ”), dated August 9, 2023, with the Institutional Investor, whereby the Company agreed to amend the following existing warrants held by such Institutional Investor","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690080/000121390023067810/0001213900-23-067810-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"the Institutional Investor"},{"label":"Effective","value":"2023-08-09"}],"fact_type":"material_agreement"},{"claim_id":"bda2f923bed52bb80d3b161c7dc4fc811dee5e34","claim":"FORUM MARKETS Inc entered into Purchase Agreement with a certain institutional investor valued at approximately $3.0 million (effective 2023-08-09).","evidence_excerpt":"On August 9, 2023, 180 Life Sciences Corp., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Purchase Agreement ”) with a certain institutional investor (the “ Institutional Investor ”) and agreed to issue and sell to certain purchasers, including the Institutional Investor, in a registered public offering (the “ Offering ”), an aggregate of: (i) 666,925 shares (the “ Shares ”) of the Company’s common stock, $0.0001 par value (the “ Common Stock ”), at a price of $0.65 per share","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690080/000121390023067810/0001213900-23-067810-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"a certain institutional investor"},{"label":"Value","value":"approximately $3.0 million"},{"label":"Effective","value":"2023-08-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}